These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30158205)

  • 21. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of smoking intensity and device cleaning on IQOS emissions: comparison with an array of cigarettes.
    Ardati O; Adeniji A; El Hage R; Salman R; El-Kaassamani M; Yassine A; Talih S; Hourani M; Karaoghlanian N; Breland A; Eissenberg T; Saliba N; Shihadeh A; El-Hellani A
    Tob Control; 2024 Jun; 33(4):449-456. PubMed ID: 36609493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical analysis of selected harmful and potentially harmful constituents and in vitro toxicological evaluation of leading flavoured e-cigarette aerosols in the Chinese market.
    Xu T; Niu ZY; Xu J; Li XD; Luo Q; Luo A; Huang YL; Jiang XT; Wu ZH
    Drug Test Anal; 2023 Oct; 15(10):1156-1163. PubMed ID: 35712913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Philip Morris International's 'aspirational' target for its 2025 cigarette shipments.
    Mehegan J; Gallagher A; Elmitwalli S; Edwards R; Gilmore A
    Tob Control; 2024 May; ():. PubMed ID: 38782585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol.
    Schaller JP; Keller D; Poget L; Pratte P; Kaelin E; McHugh D; Cudazzo G; Smart D; Tricker AR; Gautier L; Yerly M; Reis Pires R; Le Bouhellec S; Ghosh D; Hofer I; Garcia E; Vanscheeuwijck P; Maeder S
    Regul Toxicol Pharmacol; 2016 Nov; 81 Suppl 2():S27-S47. PubMed ID: 27720919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the tobacco heating system 2.2. Part 9: Application of systems pharmacology to identify exposure response markers in peripheral blood of smokers switching to THS2.2.
    Martin F; Talikka M; Ivanov NV; Haziza C; Hoeng J; Peitsch MC
    Regul Toxicol Pharmacol; 2016 Nov; 81 Suppl 2():S151-S157. PubMed ID: 27845159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative assessment of HPHC yields in the Tobacco Heating System THS2.2 and commercial cigarettes.
    Jaccard G; Tafin Djoko D; Moennikes O; Jeannet C; Kondylis A; Belushkin M
    Regul Toxicol Pharmacol; 2017 Nov; 90():1-8. PubMed ID: 28818540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette.
    Farsalinos KE; Yannovits N; Sarri T; Voudris V; Poulas K; Leischow SJ
    Addiction; 2018 Nov; 113(11):2099-2106. PubMed ID: 29920842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heat-not-burn tobacco products: an emerging threat to cardiovascular health.
    Fried ND; Gardner JD
    Am J Physiol Heart Circ Physiol; 2020 Dec; 319(6):H1234-H1239. PubMed ID: 33006919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
    Lempert LK; Glantz S
    Tob Control; 2020 Jun; ():. PubMed ID: 32601147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020.
    Sponsiello-Wang Z; Langer P; Prieto L; Dobrynina M; Skiada D; Camille N; Weitkunat R; Lüdicke F
    JMIR Res Protoc; 2019 May; 8(5):e12061. PubMed ID: 31094340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of cytotoxicity of IQOS aerosols to smoke from Marlboro Red and 3R4F reference cigarettes.
    Davis B; To V; Talbot P
    Toxicol In Vitro; 2019 Dec; 61():104652. PubMed ID: 31526836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the biological impact of aerosol of e-vapor device with MESH® technology and cigarette smoke on human bronchial and alveolar cultures.
    Giralt A; Iskandar AR; Martin F; Moschini E; Serchi T; Kondylis A; Marescotti D; Leroy P; Ortega-Torres L; Majeed S; Merg C; Trivedi K; Guedj E; Frentzel S; Ivanov NV; Peitsch MC; Gutleb AC; Hoeng J
    Toxicol Lett; 2021 Feb; 337():98-110. PubMed ID: 33220401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a greater understanding of the illicit tobacco trade in Europe: a review of the PMI funded 'Project Star' report.
    Gilmore AB; Rowell A; Gallus S; Lugo A; Joossens L; Sims M
    Tob Control; 2014 May; 23(e1):e51-61. PubMed ID: 24335339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Tobacco Heating System 2.2 (THS2.2). Part 5: microRNA expression from a 90-day rat inhalation study indicates that exposure to THS2.2 aerosol causes reduced effects on lung tissue compared with cigarette smoke.
    Sewer A; Kogel U; Talikka M; Wong ET; Martin F; Xiang Y; Guedj E; Ivanov NV; Hoeng J; Peitsch MC
    Regul Toxicol Pharmacol; 2016 Nov; 81 Suppl 2():S82-S92. PubMed ID: 27866933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.